Cognition Therapeutics (CGTX) Competitors $0.35 -0.03 (-8.24%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$0.35 0.00 (-1.19%) As of 04/4/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. AVTX, JSPR, CLSD, PYRGF, IGMS, ABOS, PYXS, AVTE, GNTA, and MNOVShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Avalo Therapeutics (AVTX), Jasper Therapeutics (JSPR), Clearside Biomedical (CLSD), PyroGenesis Canada (PYRGF), IGM Biosciences (IGMS), Acumen Pharmaceuticals (ABOS), Pyxis Oncology (PYXS), Aerovate Therapeutics (AVTE), Genenta Science (GNTA), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Avalo Therapeutics Jasper Therapeutics Clearside Biomedical PyroGenesis Canada IGM Biosciences Acumen Pharmaceuticals Pyxis Oncology Aerovate Therapeutics Genenta Science MediciNova Avalo Therapeutics (NASDAQ:AVTX) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends. Is AVTX or CGTX more profitable? Cognition Therapeutics' return on equity of -150.93% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -442.16% 122.99% Cognition Therapeutics N/A -150.93%-100.82% Does the media favor AVTX or CGTX? In the previous week, Cognition Therapeutics had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 3 mentions for Cognition Therapeutics and 2 mentions for Avalo Therapeutics. Cognition Therapeutics' average media sentiment score of 0.28 beat Avalo Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cognition Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, AVTX or CGTX? Cognition Therapeutics has lower revenue, but higher earnings than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$441K140.36-$31.54MN/AN/ACognition TherapeuticsN/AN/A-$25.79M-$0.87-0.41 Do analysts rate AVTX or CGTX? Avalo Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 468.97%. Cognition Therapeutics has a consensus price target of $7.13, suggesting a potential upside of 1,911.58%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility and risk, AVTX or CGTX? Avalo Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Does the MarketBeat Community favor AVTX or CGTX? Cognition Therapeutics received 12 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 72.73% of users gave Cognition Therapeutics an outperform vote while only 48.00% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformAvalo TherapeuticsOutperform Votes1248.00% Underperform Votes1352.00% Cognition TherapeuticsOutperform Votes2472.73% Underperform Votes927.27% Do insiders and institutionals hold more shares of AVTX or CGTX? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 43.3% of Cognition Therapeutics shares are held by institutional investors. 0.3% of Avalo Therapeutics shares are held by company insiders. Comparatively, 20.8% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCognition Therapeutics beats Avalo Therapeutics on 11 of the 15 factors compared between the two stocks. Remove Ads Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.95M$2.83B$5.26B$7.12BDividend YieldN/A1.53%4.89%4.07%P/E Ratio-0.3730.2421.3817.50Price / SalesN/A420.30355.0689.08Price / CashN/A168.6838.1834.64Price / Book0.473.486.233.79Net Income-$25.79M-$72.06M$3.21B$247.48M7 Day Performance-14.79%-12.89%-8.47%-6.79%1 Month Performance-17.82%-22.10%-4.87%-11.52%1 Year Performance-82.72%-34.52%2.54%-7.82% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics3.5636 of 5 stars$0.35-8.2%$7.13+1,911.6%-81.6%$21.95MN/A-0.3720AVTXAvalo Therapeutics2.9663 of 5 stars$7.63-0.4%$35.33+363.1%-64.4%$79.31M$820,000.000.0040JSPRJasper Therapeutics2.6559 of 5 stars$5.24+0.6%$62.50+1,092.7%-86.2%$78.72MN/A-1.1120Positive NewsCLSDClearside Biomedical2.1261 of 5 stars$1.03+2.5%$5.75+458.3%-35.3%$78.12M$7.70M-2.2930Analyst RevisionGap DownPYRGFPyroGenesis CanadaN/A$0.40+2.5%N/A+2.2%$75.59M$9.14M-6.7590High Trading VolumeIGMSIGM Biosciences4.6904 of 5 stars$1.26+5.9%$5.50+336.5%-87.3%$75.32M$2.68M-0.35190ABOSAcumen Pharmaceuticals2.5716 of 5 stars$1.24+3.3%$9.33+652.7%-74.5%$74.50MN/A-0.9020Gap DownPYXSPyxis Oncology0.999 of 5 stars$1.20-0.8%$9.20+666.7%-82.3%$73.91M$16.15M-1.1760AVTEAerovate Therapeutics0.6444 of 5 stars$2.55+1.2%$2.25-11.8%-91.4%$73.63MN/A-0.8520News CoveragePositive NewsGNTAGenenta Science2.8022 of 5 stars$4.01-3.4%$25.00+523.4%+9.7%$73.34MN/A0.007MNOVMediciNova1.542 of 5 stars$1.49-2.6%$9.00+504.0%-15.1%$73.08M$1M-6.4810 Remove Ads Related Companies and Tools Related Companies Avalo Therapeutics Competitors Jasper Therapeutics Competitors Clearside Biomedical Competitors PyroGenesis Canada Competitors IGM Biosciences Competitors Acumen Pharmaceuticals Competitors Pyxis Oncology Competitors Aerovate Therapeutics Competitors Genenta Science Competitors MediciNova Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGTX Stock Free CGTX Stock Alerts